NEW, 2-PART FORMS NOW IN CIRCULATION
After more than 30 years of using a 3-part form to monitor drugs prone to misuse, TPP Alberta has moved to a 2-part form to improve processes and save significant operational costs. Security of the form and submission requirements remain unchanged.
TPP Alberta is asking prescribers to use up their existing stock of 3-part forms before re-ordering.
Buprenorphine/naloxone moves to Type 2 medication
Effective July 15, 2019, Buprenorphine/naloxone products (with the exception of single entity buprenorphine and all buprenorphine products for veterinary use) have moved from Type 1 to Type 2 TPP Alberta status.
This means registration with TPP Alberta and use of a secure TPP prescription pad are no longer required when writing prescriptions for them.
Using Data to optimize safe patient care
TPP Alberta has been monitoring the use of prescription drugs prone to misuse since 1986.
When prescribing and dispensing data meet certain criteria, we alert physicians and others involved in the care of the patient. We provide those involved with information and direct them to helpful resources.
Information for Prescribers
Registering as a prescriber with TPP Alberta
- Prescribers must register with TPP Alberta to prescribe any medication monitored by the program.
- Medical Residents must obtain approval from their program director prior to registering with TPP Alberta.
Re-ordering TPP Alberta prescription pads
To re-order a secure pad, email TPPinfo@cpsa.ab.ca or contact 1-800 561-3899 ext 4939. Include the following information with your request:
- Your registration number
- Your clinic’s complete address including postal code
- Phone number that is to be printed on the pads
- Complete address for shipping, if different
Lost or stolen forms or pads
If your TPP Alberta pad or any of the forms are missing or stolen, you must contact the police and notify TPP Alberta immediately. The prescriber should provide the following information to TPP Alberta:
- Date of theft or loss
- Tracking number of the missing form(s) or pad(s)
- Name of the last patient prescribed a Type 1 prescription
- The police file number and investigating constable’s name and phone number
Information for Pharmacists
When to send a copy of the secure form to TPP Alberta
Dispensers only need to send a copy of the secure form (at least twice a month) to TPP Alberta when it is for:
• compounded medications
• office use
• veterinary use
• or is a Yukon prescription
Information for other tracked prescriptions is sent to TPP Alberta via Netcare/PIN. However, pharmacies should keep a copy in case TPP Alberta requests to access to it.
List of Stolen & Missing TPP Alberta Forms
Pharmacists looking for the list of stolen or missing TPP Alberta scripts can access the list through the Alberta College of Pharmacy (login required) or contact TPP Alberta directly at TPPinfo@cpsa.ab.ca or call 1-800-561-3899 ext. 4939.
Prescribers with TPP Alberta Prescribing Restrictions
Based on data from TPP Alberta, the College of Physicians & Surgeons of Alberta (CPSA) can impose prescribing conditions on physicians that restrict their prescriptive authority under certain situations. These listings and conditions are shown below:
|Surname||Given Name||Date Effective||Restrictions|
|Adams||Jim||May 9, 2019||Schedule 1 and Schedule 2 medications monitored by the Triplicate Prescription Program inclusive of methadone and all cannabinoids, except for methylphenidate.|
|Akinjise||Idowu||Jan. 13, 2019||Restricted from prescribing medications monitored by TPP Alberta, including cannabinoids and methadone, except for hospital inpatients.|
|Bassi||Amrik||Sept. 30, 2019||Restricted from prescribing medications monitored by TPP Alberta.|
|Beeharry||Raj||Sept. 1, 2017||Restricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs unless the prescription is: a. Prescribed as an anticonvulsant; b. Prescribed to a patient for a maximum of two weeks in any three month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague. Restricted from prescribing narcotic analgesics (or any products containing Codeine) unless the prescription is: a. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; b. A narcotic analgesic prescribed to a patient with acute, non-malignant pain for a maximum of two weeks for any three-month period; or c. Supported by written direction or recommendation from a consult from a specialist or knowledgeable colleague|
|Collett||Franklin Dean||Nov. 29, 2019||Prescribing restrictions for the following medications: Triplicate Prescription Program medications, anabolic steroids, methylphenidate, barbiturates, codeine containing drugs, amphetamine or amphetamine like appetite suppressants, benzodiazepines and other anxiolytics, hypnotics and sedatives, and muscle relaxants.|
|Datar||Sunil||June 23, 2016||Shall not prescribe, dispense or provide samples of any drug that is listed on the College’s Triplicate Prescription Program Product List, whether prescribed using the triplicate pad or otherwise monitored by the program, inclusive of codeine products, benzodiazepines and “Z Class Drugs”.|
|Dulai||Gurjeet Singh||March 27, 2020||Restricted from prescribing TPP Alberta (Type 1) medications except for hospital inpatients, patients in a long-term care facility and immediate administration in the emergency department. Restricted from dispensing or administering TPP Alberta (Type 2) medications.|
|Gauri||Mohammed Ali||Nov. 12, 2014||Restricted from prescribing triplicate prescriptions with the exception of opioid analgesics for malignancy-related pain documented by pathology report and/or consultant’s report.|
|Hardin||Barry Edward||Aug. 3, 2019||Restricted from prescribing medications (Type 1, Type 2, and all cannabinoids) monitored by TPP Alberta.|
|Hauptman||Robert||Oct. 23, 2019||All TPP Alberta medications, with the exclusion of stimulants.|
|Jabbari-Zadeh||Shahram||March 5, 2018||Restricted from prescribing tramadol containing medications, and any other medication on the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).|
|Jackman||Kevin F.M.||July 1, 2018||Restricted from prescribing any benzodiazepines and other anxiolytics, hypnotics and sedatives including chloral hydrate, zopiclone and other z-drugs with the following exceptions: prescribed as an anticonvulsant. Restricted from prescribing any drugs on the Triplicate Prescription Program Product List (and no products containing Codeine or tramadol) with the following exceptions: Narcotic analgesics for patients with malignancy-related pain that is documented by a pathology report or consultant’s report and non-TPP Narcotic analgesics (Codeine or Tramadol) for patients with acute non-malignant pain for a maximum of one week for each patient in any three month period.|
|Jassal||Rajive||March 7, 2019||Prescribing restrictions apply. Restricted to prescribing of TPP Type 1 and Type 2 medications, cannabinoids and methadone medications to in-patients only. In an outpatient setting, may prescribe clobazam, clonazepam, diazepam and lorazepam only to patients with a diagnosed seizure disorder.|
|Kim||Sirim||Aug. 9, 2018||Restricted from prescribing any medications on the Triplicate Medication List.|
|Kordyban||Michael||Dec. 2, 2015||Voluntarily surrenders all triplicate prescription pads under his control and shall not request resumption of prescribing of medications requiring the use of a triplicate prescription pad, in any manner.|
|Leivo||Ray||May 24, 2018||Restricted from prescribing medications monitored by the Triplicate Prescription Program, or tramadol products.|
|Lopez||Roehl||March 8, 2018||Restricted from prescribing Tramadol and any other medication on the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).|
|McAlpine||Brian Douglas||Feb. 14, 2012||Restricted from prescribing triplicate medications.Restricted from prescribing stimulant medications or medications used in the treatment of Attention Deficit Disorder.|
|McMahon||Alan||April 22, 2020||Restricted from prescribing TPP Alberta Type 1, Type 2 (not including antibiotics) and all cannabinoids.|
|McPeak||Brian K.||Aug. 28, 2019||Prescribing of Type 1 TPP Alberta medications restricted to inpatient facilities.|
|Mentz||Helena Johanna||Aug. 8, 2018||Restricted from prescribing tramadol, cannabinoids and all other medications on or monitored by the Triplicate Prescription Program Medication List (Type 1 and Type 2 medications).|
|Mohamed||Ataher S||Nov. 21, 2016||Restricted from prescribing any medication monitored by the Triplicate Prescription Program.|
|Moir||James Allan||May 12, 2017||Restricted from prescribing medications designated as part of the Triplicate Prescription Program.|
|Nakashima||Brenda Akemi||Dec. 14, 2019||Restricted from prescribing benzodiazepines and benzodiazepine-like drugs (Z drugs) monitored by the Triplicate Prescription Program except to patients for immediate administration in the Emergency Department.|
|Neu||S. Randall||Dec. 16, 2018||Restricted from prescribing triplicate medication.|
|Rosenstock||Carl||July 1, 2017||Restricted from prescribing any benzodiazepines, including chloral hydrate, zopiclone and other z-drugs with the following exceptions: 1. Prescribed as an anticonvulsant; 2. Prescribed to a patient for a maximum of two weeks in any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague. Restricted from prescribing any drugs on the Triplicate Prescription Program List (or any products containing Codeine) with the following exceptions: 1. A narcotic analgesic prescribed to a patient with malignancy-related pain that is documented by a pathology report or consultant’s report; 2. A narcotic analgesic prescribed to a patient with acute non-malignant pain for a maximum of two weeks for any three month period; or 3. Supported by a direction or recommendation arising from a consult from a specialist or knowledgeable colleague.|
|Sheps||David M.||Feb. 23, 2018||Restricted from prescribing Tramadol and any medications on the Triplicate Prescription Program medications list.|
|Swart||Johan||Dec. 14, 2017||Restricted from prescribing Tramadol products or medications on either of the schedules of the Triplicate Prescribing Program.|
|Thakur||Nathan||Oct. 7, 2019||Psychotropic medications, opioids including Suboxone and methadone, benzodiazepines and cannabinoids to female patients greater than the age of 16 years.|
|Thompson||Robert Douglas||July 4, 2013||Restricted from prescribing any medications which require a Triplicate Prescription pad.|
|Warneke||Lorne||Feb. 4, 2019||Restricted from prescribing any triplicate medications and any stimulant medication including Dexedrine, Concerta, and Biphentin.|
|Werkman||Isabella||March 1, 2020||Restricted from prescribing opioid medications, methadone, Suboxone and cannabinoids.|
|White||Roger Tyler||Aug. 1, 2015||Discontinue providing medications of potential abuse including triplicate program medications and benzodiazepines.|
Eligible prescribers (physicians, podiatric physicians, nurse practitioners, dentists and veterinarians) may apply to TPP Alberta by completing the Registration form for Prescribers or the Registration form for Medical Residents.
NOTE: Registration is only required for prescribing Type 1 medications. Type 2 medications do not have special prescribing requirements but are monitored by TPP Alberta through Netcare, PIN.
TPP Alberta Resources
- TPP Alberta Medications List
- Cannabis for Medical Purposes
- Sample Treatment Agreement Template
- TPP Alberta – OME and DDD Conversion Factors
- TPP Atlas – Highlights provincial use of medications monitored by TPP Alberta in a given year.
- TPP Alberta Annual Report – Provides a comprehensive summary of program activities throughout the preceding year.
TPP Alberta is funded primarily by the provincial government and administered by the CPSA. TPP Alberta partners are: